RESEARCH ARTICLE

Design, molecular docking, synthesis, characterization, biological activity evaluation (against MES model), in-silico biological activity spectrum (PASS analysis), toxicological and predicted oral rat LD50 studies of novel sulphonamide derivatives

  • Ajeet , 1 ,
  • Arvind Kumar 2 ,
  • Arun K. Mishra 1
Expand
  • 1. Drug Design Laboratory, School of Pharmaceutical Sciences, IFTM University, Moradabad, Uttar Pradesh, India
  • 2. Department of Pharmaceutical Chemistry, S. D. College of Pharmacy and Vocational Studies, Muzaffarnagar, Uttar Pradesh, India

Received date: 05 Jun 2018

Accepted date: 10 Jul 2018

Published date: 30 Nov 2018

Copyright

2018 Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature

Abstract

BACKGROUND: Among the reported potential agents to treat the epilepsy, sulphonamides are important and their significance cannot be ignored. A series of substituted 4-amino-benzene sulfonamides were designed, keeping in view the structural requirement of pharmacophore.

METHODS: Lipinski rule of five has been calculated; failure to Lipinski rule was not observed. Docking was performed through AutoDock Vina. Molecules have been screened out through docking. Compounds were synthesized and characterized through IR, 1HNMR, 13C NMR, Mass and elemental analysis. The anticonvulsant activity of the synthesized compounds was assessed using the Maximal Electroshock Seizure (MES) model. In-silico biological activity spectrum, toxicological studies, predicted oral rats LD50 were performed.

RESULTS: Docking studies showed good interaction with lyase (Oxo-acid) - human carbonic anhydrase-I (1AZM). The in-silico studies proved them to be with good drug-likeness properties, especially 4-(3-Acetyl-phenylamino)-methyl)-benzenesulfonamide (2g). These results revealed that the synthesized compounds (1a-1c, 2a-2q) exhibited promising anticonvulsant effect against MES model for inhibition of Lyase- Human Carbonic Anhydrase-I.

CONCLUSION: After investigating all the results, the compound 4-(3-Acetyl-phenylamino)-methyl)-benzenesulfonamide (2g) is found to be best in the series. A comparatively good activity of compound 2g suggests us that sulphonamide can be leads to further optimization for building potent and chemically diversified anti-convulsant agents.

Cite this article

Ajeet , Arvind Kumar , Arun K. Mishra . Design, molecular docking, synthesis, characterization, biological activity evaluation (against MES model), in-silico biological activity spectrum (PASS analysis), toxicological and predicted oral rat LD50 studies of novel sulphonamide derivatives[J]. Frontiers in Biology, 2018 , 13(6) : 425 -451 . DOI: 10.1007/s11515-018-1512-4

Acknowledgment

One of the authors (Ajeet) is thankful to Ms. Pratibha Priti Maurya, Owner, CBBE, India for in-silico studies, and thankful to Dr. Om Prakash, Post Doctorate Fellow, University of Lucknow, India for interpretation and support of In-silico studies.

Author’s contribution

Ajeet conceptualized overall study design and carried synthesis, biological studies, analyzed and interpreted data. Dr. Arvind Kumar and Dr. Arun Kumar Mishra analyzed and revised the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Permission was sought from Institutional Animal Ethics Committee, IFTM University, India for carrying biological studies (Animal studies) under Registration No. 837/ac/04/CPCSEA and Resolution No. 2015/837ac/PhD/04.

Conflicts of interest

None conflict of interest declared.
1
Barry Wood W (1942). Studies on the antibacterial action of the sulfonamide drugs. J Exp Med, 75(4): 369–381

DOI PMID

2
Bialk H M, Simpson A J, Pedersen J A (2005). Cross-coupling of sulfonamide antimicrobial agents with model humic constituents. Environ Sci Technol, 39(12): 4463–4473

DOI PMID

3
Capasso C, Supuran C T (2015). An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem, 30(2): 325–332

DOI PMID

4
De Simone G, Scozzafava A, Supuran C T (2009). Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des, 74(3): 317–321

DOI PMID

5
Filimonov D A, Poroikov V V, Karaicheva E I, Kazarian R K, Budunova A P, Mikhailovskii E M, Rudnitskikh A V, Goncharenko L V, Burov Yu V (1995). Computer-Aided Prediction of Biological Activity Spectra of Chemical Substances on the Basis of Their Structural Formulae: Computerized System PASS. Experimental and Clinical Pharmacology(Rus), 58(2): 56–62

6
Hen N, Bialer M, Wlodarczyk B, Finnell R H, Yagen B (2010). Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide. J Med Chem, 53(10): 4177–4186

DOI PMID

7
Leeson P (2012). Drug discovery: Chemical beauty contest. Nature, 481(7382): 455–456

DOI PMID

8
Malawska B, Scatturin A (2003). Application of pharmacophore models for the design and synthesis of new anticonvulsant drugs. Mini Rev Med Chem, 3(4): 341–348

DOI PMID

9
Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran C T (2002). Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem, 45(2): 312–320

DOI PMID

10
Perrin H L, Bliss E A (1937). Para-aminobenzenesulfonamide and its derivatives experimental and clinical observations on their use in the treatment of betahemolytic streptococcic infection: a preliminary report. J. Am. Med. Soc., 108(1): 32–37

11
Price T, Sammons G, Zachry D (1952). Antitubercular Studies. V. 4-Aminobenzamides and 4-Aminobenzenesulfonamides. J Am Chem Soc, 74(23): 5961–5963

DOI

12
Reynolds C H, Merz K M, Ringe D( 2010 ) . Drug Design: Structure- And Ligand-Based Approaches, Cambridge University Press, Cambridge UK

13
Reynolds E H (2002). Epilepsy in the world: Launch of the second phase of the ILAE/IBE/WHO global campaign against epilepsy. Epilepsia, 43(supp. 6): 1–3

DOI PMID

14
Satischandra P, Gururaj G, Mohammed Q D, Senanayake N, Silpakit O, Dekker P A( 2005). Epilepsy: A manual for physicians. World Health Organization, New Delhi.1–15

15
Supuran C T (2008). Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov, 7(2): 168–181

DOI PMID

16
Thiry A, Dogné J M, Supuran C T, Masereel B (2007). Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem, 7(9): 855–864

DOI PMID

17
Thiry A, Dogné J M, Supuran C T, Masereel B (2008). Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action. Curr Pharm Des, 14(7): 661–671

DOI PMID

18
Tripathi L, Kumar P, Singh R, Stables J P (2012). Design, synthesis and anticonvulsant evaluation of novel N-(4-substituted phenyl)-2-(4-(substituted) benzylidene)-hydrazinecarbothio amides. Eur J Med Chem, 47(1): 153–166

DOI PMID

19
Trott O, Olson A J (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem, 31(2): 455–461

PMID

20
Vannada J, Bennett E M, Wilson D J, Boshoff H I, Barry C E 3rd, Aldrich C C (2006). Design, synthesis, and biological evaluation of beta-ketosulfonamide adenylation inhibitors as potential antitubercular agents. Org Lett, 8(21): 4707–4710

DOI PMID

21
Venkatapathy R, Moudgal C J, Bruce R M (2004). Assessment of the oral rat chronic lowest observed adverse effect level model in TOPKAT, a QSAR software package for toxicity prediction. J Chem Inf Comput Sci, 44(5): 1623–1629

DOI PMID

22
Zimmerman S, Innocenti A, Casini A, Ferry J G, Scozzafava A, Supuran C T (2004). Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. Bioorg Med Chem Lett, 14(24): 6001–6006

DOI PMID

Outlines

/